Ofer Agid

Summary

Affiliation: Centre for Addiction and Mental Health
Country: Canada

Publications

  1. ncbi request reprint Early use of clozapine for poorly responding first-episode psychosis
    Ofer Agid
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    J Clin Psychopharmacol 27:369-73. 2007
  2. doi request reprint An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis
    Ofer Agid
    Schizophrenia Program, Centre for Addiction and Mental Health, 250 College St, Toronto, Ontario, M5T 1R8, Canada
    J Clin Psychiatry 72:1439-44. 2011
  3. ncbi request reprint Emerging drugs for schizophrenia
    Ofer Agid
    Centre for Addiction and Mental Health, Schizophrenia Program, Department of Psychiatry, University of Toronto, 250 College Street, Toronto, Ontario M5T 1R8, Canada
    Expert Opin Emerg Drugs 13:479-95. 2008
  4. doi request reprint Early prediction of clinical and functional outcome in schizophrenia
    Ofer Agid
    Schizophrenia Program, Center for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, Canada
    Eur Neuropsychopharmacol 23:842-51. 2013
  5. ncbi request reprint Where to position clozapine: re-examining the evidence
    Ofer Agid
    Schizophrenia Program, Centre for Addiction and Mental Health, Toronto, Ontario
    Can J Psychiatry 55:677-84. 2010
  6. doi request reprint Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention
    Ofer Agid
    Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
    Expert Opin Pharmacother 11:2301-17. 2010
  7. doi request reprint Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders
    Ofer Agid
    Center for Addiction and Mental Health, 250 College St, Toronto, Ontario, Canada M5T 1R8
    Schizophr Res 102:241-8. 2008
  8. doi request reprint Tetrabenazine augmentation in treatment-resistant schizophrenia: a 12-week, double-blind, placebo-controlled trial
    Gary Remington
    Department of Psychiatry, University of Toronto, Toronto, Canada
    J Clin Psychopharmacol 32:95-9. 2012
  9. doi request reprint Clozapine's role in the treatment of first-episode schizophrenia
    Gary Remington
    Department of Psychiatry, University of Toronto, Canada
    Am J Psychiatry 170:146-51. 2013
  10. doi request reprint Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia
    Takefumi Suzuki
    Centre for Addiction and Mental Health, Geriatric Mental Health Program and Multimodal Imaging Group, and Department of Psychiatry, University of Toronto, Ontario, Canada, and Keio University School of Medicine, Department of Neuropsychiatry, Tokyo, Japan
    Br J Psychiatry 199:275-80. 2011

Detail Information

Publications45

  1. ncbi request reprint Early use of clozapine for poorly responding first-episode psychosis
    Ofer Agid
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    J Clin Psychopharmacol 27:369-73. 2007
    ..The present findings suggest that clozapine may have an important role in the early treatment of first-episode patients whose psychosis does not remit with other second-generation antipsychotics during the first months of treatment...
  2. doi request reprint An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis
    Ofer Agid
    Schizophrenia Program, Centre for Addiction and Mental Health, 250 College St, Toronto, Ontario, M5T 1R8, Canada
    J Clin Psychiatry 72:1439-44. 2011
    ..Employing a naturalistic design, we examined response rates over 3 circumscribed antipsychotic trials...
  3. ncbi request reprint Emerging drugs for schizophrenia
    Ofer Agid
    Centre for Addiction and Mental Health, Schizophrenia Program, Department of Psychiatry, University of Toronto, 250 College Street, Toronto, Ontario M5T 1R8, Canada
    Expert Opin Emerg Drugs 13:479-95. 2008
    ..As the dust settles on this period and substantial data, as well as practical prescribing experience, are available, we examine what has been gained and what can be learned...
  4. doi request reprint Early prediction of clinical and functional outcome in schizophrenia
    Ofer Agid
    Schizophrenia Program, Center for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, Canada
    Eur Neuropsychopharmacol 23:842-51. 2013
    ....
  5. ncbi request reprint Where to position clozapine: re-examining the evidence
    Ofer Agid
    Schizophrenia Program, Centre for Addiction and Mental Health, Toronto, Ontario
    Can J Psychiatry 55:677-84. 2010
    ..To review clozapine's position in treatment algorithms for schizophrenia...
  6. doi request reprint Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention
    Ofer Agid
    Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
    Expert Opin Pharmacother 11:2301-17. 2010
    ..However, nonadherence with antipsychotic treatment is a significant issue, with estimates as high as 90%...
  7. doi request reprint Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders
    Ofer Agid
    Center for Addiction and Mental Health, 250 College St, Toronto, Ontario, Canada M5T 1R8
    Schizophr Res 102:241-8. 2008
    ..The objective of this study was to evaluate the early response (within the first 24 h) in psychosis with ziprasidone IM treatment, and to determine whether this early effect is distinct from a reduction in agitation symptoms...
  8. doi request reprint Tetrabenazine augmentation in treatment-resistant schizophrenia: a 12-week, double-blind, placebo-controlled trial
    Gary Remington
    Department of Psychiatry, University of Toronto, Toronto, Canada
    J Clin Psychopharmacol 32:95-9. 2012
    ....
  9. doi request reprint Clozapine's role in the treatment of first-episode schizophrenia
    Gary Remington
    Department of Psychiatry, University of Toronto, Canada
    Am J Psychiatry 170:146-51. 2013
    ....
  10. doi request reprint Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia
    Takefumi Suzuki
    Centre for Addiction and Mental Health, Geriatric Mental Health Program and Multimodal Imaging Group, and Department of Psychiatry, University of Toronto, Ontario, Canada, and Keio University School of Medicine, Department of Neuropsychiatry, Tokyo, Japan
    Br J Psychiatry 199:275-80. 2011
    ..Improvements are greatest in the earlier weeks of antipsychotic treatment of patients with non-resistant schizophrenia...
  11. ncbi request reprint Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia
    Romina Mizrahi
    Centre for Addiction and Mental Health, Toronto, Ontario, Canada M5S 2S1
    Am J Psychiatry 164:630-7. 2007
    ..The authors present the first double-blind controlled study to examine the relationship between striatal and extrastriatal dopamine D(2) receptor binding potential and occupancy values and adverse subjective experience...
  12. doi request reprint The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study
    Ariel Graff-Guerrero
    PET Centre, Centre for Addiction and Mental Health, Toronto, Canada
    Neuropsychopharmacology 34:1078-86. 2009
    ..It is possible that receptors with high affinity are not accessible by [(11)C]-(+)-PHNO because they are occupied by endogenous dopamine, a possibility that can be ruled out in future experiments...
  13. doi request reprint Clinical determinants of life satisfaction in chronic schizophrenia: data from the CATIE study
    Gagan Fervaha
    Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, Canada Institute of Medical Science, University of Toronto, Toronto, Canada Electronic address
    Schizophr Res 151:203-8. 2013
    ..The present study sought to focus on global life satisfaction as a key subjective domain and determine its relationship with clinical variables...
  14. doi request reprint Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching
    Ofer Agid
    Centre for Addiction and Mental Health, Ontario, Canada Department of Psychiatry, University of Toronto, Ontario, Canada
    Eur Neuropsychopharmacol 23:1017-22. 2013
    ..It remains to be established whether further antipsychotic trials are associated with even greater decrements in rate of response. Findings underscore the importance of moving to clozapine when treatment resistance has been established. ..
  15. doi request reprint Incentive motivation deficits in schizophrenia reflect effort computation impairments during cost-benefit decision-making
    Gagan Fervaha
    Schizophrenia Division, Centre for Addiction and Mental Health, 250 College Street, Toronto, ON, Canada M5T 1R8 Institute of Medical Science, University of Toronto, Toronto, ON, Canada Electronic address
    J Psychiatr Res 47:1590-6. 2013
    ..Here, we use a translational paradigm to measure incentive motivation in individuals with schizophrenia...
  16. ncbi request reprint Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia
    Ofer Agid
    Schizophrenia Program, Centre for Addiction and Mental Health, Toronto, ON, Canada
    Neuropsychopharmacology 32:1209-15. 2007
    ....
  17. doi request reprint Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO
    Romina Mizrahi
    PET Centre, Centre for Addiction and Mental Health, Toronto, Canada
    Schizophr Res 131:63-8. 2011
    ..11)C]-(+)-PHNO offer new opportunities for exploring the potential therapeutic significance of the D(3) receptor in schizophrenia and the action of antipsychotics...
  18. doi request reprint Neural substrates underlying effort computation in schizophrenia
    Gagan Fervaha
    Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, Canada Institute of Medical Science, University of Toronto, Toronto, Canada Electronic address
    Neurosci Biobehav Rev 37:2649-65. 2013
    ..Lastly, we shall discuss future directions of research that may assist in shedding light on the neurobiology of effort cost computations in schizophrenia. ..
  19. doi request reprint Happiness in first-episode schizophrenia
    Ofer Agid
    Department of Psychiatry, Faculty of Medicine, University of Toronto, Canada
    Schizophr Res 141:98-103. 2012
    ..The present study set out to specifically assess happiness in schizophrenia in relation to both clinical and functional measures of outcome...
  20. ncbi request reprint Evidence for onset of antipsychotic effects within the first 24 hours of treatment
    Shitij Kapur
    Centre for Addiction and Mental Health, 250 College St, Toronto, Ont, Canada M5R 1T8
    Am J Psychiatry 162:939-46. 2005
    ..Recent research has shown that antipsychotic action begins within the first week. The authors tested the hypothesis that psychosis improves within the first 24 hours of antipsychotic treatment...
  21. doi request reprint Extrapyramidal symptoms and cognitive test performance in patients with schizophrenia
    Gagan Fervaha
    Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, Canada Institute of Medical Science, University of Toronto, Toronto, Canada Electronic address
    Schizophr Res 161:351-6. 2015
    ..Extrapyramidal symptoms (EPS) are among the most common abnormal movements in schizophrenia, but their relationship with other features of the illness such as cognition is not well characterized...
  22. pmc What does schizophrenia teach us about antipsychotics?
    Gary Remington
    Professor, Department of Psychiatry, University of Toronto, Toronto, Ontario Lead, Subspecialty Clinics, Schizophrenia Program, Centre for Addiction and Mental Health, Toronto, Ontario Senior Scientist, Campbell Family Mental Health Research Institute, Toronto, Ontario Faculty, Institute of Medical Science, Toronto, Ontario
    Can J Psychiatry 60:S14-8. 2015
    ..To examine how advances in our understanding of schizophrenia have shaped thinking about antipsychotics (APs) and their role in treatment...
  23. doi request reprint Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?
    Gary Remington
    Schizophrenia Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Psychopharmacology (Berl) 225:505-18. 2013
    ..A safety-related threshold has also been proposed, as well as therapeutic lower and upper thresholds. While there has been reasonable consensus regarding a lower therapeutic threshold, this is not the case for the upper thresholds...
  24. ncbi request reprint Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected
    Ofer Agid
    Schizophrenia Program and the PET Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Arch Gen Psychiatry 60:1228-35. 2003
    ..To understand the mechanism of action of antipsychotic drugs, it is critical to recognize the time course over which these medications take effect. Current models of antipsychotic action presume a "delayed onset" of action...
  25. doi request reprint Progress in defining optimal treatment outcome in schizophrenia
    Gary Remington
    Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
    CNS Drugs 24:9-20. 2010
    ..To this end, the field has now embraced a recovery model that is seen as a process, multidimensional and individualized, rather than dichotomous and symptom driven...
  26. doi request reprint Determinants of patient-rated and clinician-rated illness severity in schizophrenia
    Gagan Fervaha
    Schizophrenia Division, Centre for Addiction and Mental Health, 250 College St, Room 320, Toronto, Ontario, Canada M5T 1R8
    J Clin Psychiatry 76:924-30. 2015
    ..The present study examined the clinical determinants of clinician and patient ratings of overall illness severity...
  27. pmc Antipsychotics and amotivation
    Gagan Fervaha
    1 Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, Canada 2 Institute of Medical Science, University of Toronto, Toronto, Canada
    Neuropsychopharmacology 40:1539-48. 2015
    ..It is possible that the negative impact of antipsychotics in this regard is overstated; conversely, the present results also indicate that we must look beyond antipsychotics in our efforts to improve motivation. ..
  28. doi request reprint Relationship between symptomatic improvement and overall illness severity in patients with schizophrenia
    Gagan Fervaha
    From the Schizophrenia Division, Centre for Addiction and Mental Health and Institute of Medical Science, and Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    J Clin Psychopharmacol 35:128-33. 2015
    ..The present study examined the independent relationships between improvement in specific symptom clusters and change in global impressions of illness severity...
  29. doi request reprint Motivational deficits and cognitive test performance in schizophrenia
    Gagan Fervaha
    Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, Ontario, Canada2Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
    JAMA Psychiatry 71:1058-65. 2014
    ..Although poor effort and decreased motivation are known to affect performance on cognitive tests, the extent of this relationship is unclear in patients with schizophrenia...
  30. doi request reprint Clinical and functional outcomes in people with schizophrenia with a high sense of well-being
    Gagan Fervaha
    Schizophrenia Division, Centre for Addiction and Mental Health and Institute of Medical Science and Department of Psychiatry, University of Toronto, Toronto, Canada
    J Nerv Ment Dis 203:187-93. 2015
    ..Those involved in care should be aware that life satisfaction as an outcome is not necessarily associated with symptom remission and superior functioning. ..
  31. doi request reprint The neurobiology of relapse in schizophrenia
    Gary Remington
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada Centre for Addiction and Mental Health CAMH, Toronto, Ontario, Canada Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada Campbell Family Mental Health Research Institute, Toronto, Ontario, Canada Electronic address
    Schizophr Res 152:381-90. 2014
    ..We propose that it is shaped by the form of illness and in place from the outset, modified by constitutional factors like resilience, as well as treatment, and confounded by secondary forms of relapse. ..
  32. doi request reprint Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment
    Gary Remington
    University of Toronto, Toronto, Ontario, Canada
    Expert Rev Neurother 11:589-607. 2011
    ..This shift in thinking has important theoretical implications from the standpoint of etiology and pathophysiology, but also clinically in terms of treatment and drug development...
  33. doi request reprint Effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia
    Hiroyoshi Takeuchi
    Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, ON, Canada Department of Psychiatry, University of Toronto, Toronto, ON, Canada Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan Electronic address
    Eur Neuropsychopharmacol 25:295-302. 2015
    ..However, in view of the lower mean dose and better side effect profile, it is advisable to adhere to a once-daily dosing regimen, especially in the case of olanzapine. ..
  34. doi request reprint Dissecting negative symptoms in schizophrenia: opportunities for translation into new treatments
    George Foussias
    Campbell Family Mental Health Research Institute, and Schizophrenia Division Complex Mental Illness Program, Centre for Addiction and Mental Health, Toronto, ON, Canada Department of Psychiatry, University of Toronto, Toronto, ON, Canada Institute of Medical Science, University of Toronto, Toronto, ON, Canada
    J Psychopharmacol 29:116-26. 2015
    ....
  35. doi request reprint Daily activity patterns in remitted first-episode schizophrenia
    Gagan Fervaha
    Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, Canada Institute of Medical Science, University of Toronto, Toronto, Canada Electronic address
    Compr Psychiatry 55:1182-7. 2014
    ..The present investigation set out to examine the daily activity patterns of remitted first-episode patients with schizophrenia...
  36. doi request reprint Effect of antipsychotic medication on overall life satisfaction among individuals with chronic schizophrenia: findings from the NIMH CATIE study
    Gagan Fervaha
    Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, Ontario, Canada M5T 1R8 Institute of Medical Science, University of Toronto, Toronto, Canada Electronic address
    Eur Neuropsychopharmacol 24:1078-85. 2014
    ..Clinicians should be aware that these two domains are not inextricably linked. ..
  37. doi request reprint Specialized home treatment versus hospital-based outpatient treatment for first-episode psychosis: a randomized clinical trial
    Carolyn S Dewa
    Health Systems Research and Consulting Unit, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada
    Early Interv Psychiatry 3:304-11. 2009
    ..This pilot study compared the effectiveness of specialized care that was home based versus hospital based for individuals experiencing their first psychotic episode...
  38. pmc How antipsychotics work-from receptors to reality
    Shitij Kapur
    Centre for Addiction and Mental Health, Toronto, Canada M5S 1A1 University of Toronto, Toronto, Canada
    NeuroRx 3:10-21. 2006
    ..The implications of these findings for clinical care, animal models, future target discovery and drug development are discussed...
  39. pmc Antipsychotic dosing: found in translation
    Gary Remington
    The Department of Psychiatry, University of Toronto, Toronto, Ont, Institute of Medical Science, University of Toronto, Toronto, Ont, Centre for Addiction and Mental Health CAMH, Toronto, Ont, and The Campbell Family Mental Health Research Institute, Toronto, Ont, Canada
    J Psychiatry Neurosci 39:223-31. 2014
    ....
  40. doi request reprint Abbreviated quality of life scales for schizophrenia: comparison and utility of two brief community functioning measures
    Gagan Fervaha
    Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, Canada Institute of Medical Science, University of Toronto, Toronto, Canada Electronic address
    Schizophr Res 154:89-92. 2014
    ..The present study examined the validity and utility of two abbreviated QLS measures against the full QLS excluding negative symptom items...
  41. doi request reprint Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders
    George Foussias
    Centre for Addiction and Mental Health, University of Toronto, 250 College Street, Toronto, Ontario, Canada M5T 1R8 Department of Psychiatry, University of Toronto, 250 College Street, Toronto, Ontario, Canada M5T 1R8 Institute of Medical Science, Faculty of Medicine, University of Toronto, Medical Sciences Building, 1 King s College Circle, Toronto, Ontario, Canada M5S 1A8 Electronic address
    Eur Neuropsychopharmacol 24:693-709. 2014
    ....
  42. doi request reprint Toward a more parsimonious assessment of neurocognition in schizophrenia: a 10-minute assessment tool
    Gagan Fervaha
    Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, Canada Institute of Medical Science, University of Toronto, Toronto, Canada Electronic address
    J Psychiatr Res 52:50-6. 2014
    ..The present study examined whether a brief neurocognitive assessment (BNA) instrument could effectively estimate global neurocognition and further examined its clinical utility...
  43. doi request reprint Amotivation and functional outcomes in early schizophrenia
    Gagan Fervaha
    Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, ON, Canada Institute of Medical Science, University of Toronto, Toronto, ON, Canada Electronic address
    Psychiatry Res 210:665-8. 2013
    ..This relationship remained robust even after controlling for other clinical variables. These data suggest amotivation is core to functioning across the disease course...
  44. pmc The "delayed onset" of antipsychotic action--an idea whose time has come and gone
    Ofer Agid
    Centre for Addiction and Mental Health, Toronto, Ont
    J Psychiatry Neurosci 31:93-100. 2006
    ..The implications of this finding for clinical decision-making, mechanisms of antipsychotic action and drug discovery are discussed...
  45. ncbi request reprint Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics
    Johannes Tauscher
    University of Toronto Department of Psychiatry, Schizophrenia Program
    Am J Psychiatry 161:1620-5. 2004
    ....